[Evaluation of the leuko-reductive efficacy of single-donor erythropheresis procedures].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Medarde.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We have studied serological markers of viral hepatitis type A, B, delta and C in 7,713 blood-donors, 265 patients with a clinical diagnosis of hepatitis, 41 inmates of a mental and physical retardation institution and 41 health care workers at the same institution and 35 chronic hemodialysis patients. The results showed a 0.8% anti-HCV prevalence in blood-donors, but a higher percentage (47.5%) among HBV positive patients and in two different groups of the inmates at the mental institution (12.5% and 36%). We can not establish a relationship with the presence of anti-HCV and serological markers for HBV or H-delta V, neither with any serological markers pattern of B hepatitis nor with the anti-HCV levels and pathological findings in the biopsy of the cases in which this procedure was performed. The detection of anti-HCV has two direct applications: to exclude positive blood-donors in order to reduce the risk of post-transfusion hepatitis and to better establish a precise diagnosis in patients otherwise classified of having nonA-nonB hepatitis.
The following is a review of the data of hepatitis-B serology study obtained during the last sixteen years in the Blood Bank of Navarra. The prevalence of HBsAg carriers is 0.87% (204 positive cases in 23,409 blood donors studied). The methods used during this period have been: AGD (7 positive donors, i.e. 3.4%), CIEP (4 positive donors, i.e. 1.9%), HARP (78 positive donors, i.e. 38.2%), EIA (93 positive donors, i.e. 45.5%) and RIA (22 positive donors, i.e. 10.7%). The number of previous donations before the detection of HBsAg dropped from 7/8 in the first group of donors to 4/5 in the second and to 1 in the third group. A deeper study has been carried out in 120 of those blood donors, including the detection of anti-HBs, anti-HBc, HBeAg and anti-HBe. A low-infectivity pattern has been found in 92 (76.6%), high infectivity in 4 (3.3%) and seroconversion in 16 (13.3%). It hasn't been possible to interpret the pattern of the remaining 8 (6.6%). Both the sensitivity and the specificity of our actual screening method have been found adequate in a cooperative study carried out in a group of Blood Banks in Spain in 1985.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.